For the second year in a row, spending on medicines in 2015 grew by double-digits, increasing 12.2% on an invoice basis to $424.8 billion, according to the IMS Institute for Healthcare Informatics’ medicine report on spending for 2015.
With the acquisition, Pfizer gains Bamboo’s gene therapy expertise, as well as an advanced recombinant Adeno-associated virus (rAAV) vector design and production technology and a gene therapy manufacturing facility for Phase I/II materials.
Reuters is reporting that the FDA’s Arthritis Advisory Board has unanimously recommended Amgen’s biosimilar of AbbVie’s Humira, ABP 501. The panel said that the drug was similar in safety and effectiveness to Humira for rheumatoid arthritis and plaque psoriasis, and it recommended that the biosimilar should also be approved for Crohn’s disease in adults and ulcerative colitis. (Reuters)
Under the partnership, Ultragenyx will initially receive an exclusive license for one of Takeda’s preclinical product candidates in a pre-determined field of use, along with the option to co-develop and co-commercialize the candidate in other therapeutic areas.
In a new report, the IMS Institute for Healthcare Informatics examines the growth in the oncology market in 2015 while looking forward to 2020 and examining the ways new cancer treatments are changing the healthcare landscape in terms of cost and distribution.